Prevention of venous thromboembolism in obesity

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 12, 2010, Pages 1711-1721

  Freeman, Andrew L ^a,b   Pendleton, Robert C ^a,b   Rondina, Matthew T ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

deep vein thrombosis; fondaparinux; low molecular weight heparin; morbid obesity; pulmonary embolism; special populations; venous thromboembolism prophylaxis

Indexed keywords

DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PARNAPARIN; TINZAPARIN;

BARIATRIC SURGERY; BODY MASS; COMPRESSION GARMENT; COMPRESSION THERAPY; DRUG DOSE COMPARISON; DRUG MECHANISM; HUMAN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LOW DRUG DOSE; OBESITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; THROMBOSIS PREVENTION; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; BARIATRIC SURGERY; COMBINED MODALITY THERAPY; DRUG MONITORING; HUMANS; OBESITY; OBESITY, MORBID; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; PULMONARY EMBOLISM; RISK FACTORS; SOCIETIES, MEDICAL; STOCKINGS, COMPRESSION; VENA CAVA FILTERS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 78649658568     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.160     Document Type: Review

References (66)

1. Spyropoulos AC, Mahan C. Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives. Am. J. Med. 122, 1077-1084 (2009).
2. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch. Intern. Med. 167, 1471-1475 (2007).
3. Anderson FA Jr, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Intern. Med. 151, 933-938 (1991).
4. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 381S-453S (2008).
5. Berlot G, Calderan C, Vergolini A et al. Pulmonary embolism in critically ill patients receiving antithrombotic prophylaxis: a clinical-pathologic study. J. Crit. Care DOI:10.1016/j.jcrc.2010.04.004 (2010) (Epub ahead of print).
6. Samama MM, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N. Engl. J. Med. 341, 793-800 (1999).
7. Spyropoulos AC. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Chest 128, 958-969 (2005).
8. Dhillon S, Plosker GL. Fondaparinux: use in thromboprophylaxis of acute medical patients. Drugs Aging 25, 81-88 (2008).
9. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110, 874-879 (2004).
10. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117, 93-102 (2008).
11. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am. J. Med. 118, 978-980 (2005).
12. Goldhaber SZ, Grodstein F, Stampfer MJ et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 277, 642-645 (1997). (Pubitemid 27097428)
13. Goldhaber SZ, Savage DD, Garrison RJ et al. Risk factors for pulmonary embolism. The Framingham Study. Am. J. Med. 74, 1023-1028 (1983).
14. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303, 235-241 (2010).
15. Snell AM. The relation of obesity to fatal post-operative pulmonary embolism. Arch. Surg. 15, 237-244 (1927).
16. Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: 'the study of men born in 1913'. Arch. Intern. Med. 159, 1886-1890 (1999).
17. Kabrhel C, Varraso R, Goldhaber SZ, Rimm EB, Camargo CA. Prospective study of BMI and the risk of pulmonary embolism in women. Obesity (Silver Spring) 17, 2040-2046 (2009).
18. Severinsen MT, Overvad K, Johnsen SP et al. Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br. J. Haematol. 149, 273-279 (2010).
19. Stein PD, Goldman J. Obesity and thromboembolic disease. Clin. Chest. Med. 30, 489-493, viii (2009).
20. Eichinger S, Hron G, Bialonczyk C et al Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch. Intern. Med. 168, 1678-1683 (2008).
21. Faber DR, de Groot PG, Visseren FL. Role of adipose tissue in haemostasis, coagulation and fbrinolysis. Obes. Rev. 10, 554-563 (2009).
22. Napoleone E, A DIS, Amore C et al. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? J. Thromb. Haemost. 5, 1462-1468 (2007).
23. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat. Med. 9, 458-462 (2003).
24. Kopp CW, Kopp HP, Steiner S et al Weight loss reduces tissue factor in morbidly obese patients. Obes. Res. 11, 950-956 (2003).
25. Ay L, Kopp HP, Brix JM et al. Thrombin generation in morbid obesity: signifcant reduction after weight loss. J. Thromb. Haemost. 8, 759-765 (2010).
26. Hosogai N, Fukuhara A, Oshima K et al Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56, 901-911 (2007).
27. Lopez JA, Chen J. Pathophysiology of venous thrombosis. Thromb. Res. 123, S30-S34 (2009).
28. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet. 49, 71-87 (2010).
29. Imberti D, Legnani C, Baldini E et al Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thromb. Res. 124, 667-671 (2009).
30. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 188S-203S (2004). (Pubitemid 39297954)
31. Shepherd MF, Rosborough TK, Schwartz ML. Heparin thromboprophylaxis in gastric bypass surgery. Obes. Surg 13, 249-253 (2003).
32. Shepherd MF, Rosborough TK, Schwartz ML. Unfractionated heparin infusion for thromboprophylaxis in highest risk gastric bypass surgery. Obes. Surg. 14, 601-605 (2004).
33. Quebbemann B, Akhondzadeh M, Dallal R. Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. Obes. Surg. 15, 1221-1224 (2005).
34. Samama MM, Verhille C, Carchy L. Relation between weight, obesity, and frequency of deep vein thrombosis after enoxaparin in orthopedic surgery. Thromb. Haemost. 73, 977 (1995) (Abstract 300).
35. Tripodi A, van den Besselaar A. Laboratory monitoring of anticoagulation: where do we stand? Semin. Thromb. Hemost. 35, 34-41 (2009).
36. Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J. Thromb. Haemost. 2, 551-554 (2004). (Pubitemid 40185676)
37. Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J. Thromb. Haemost. 2, 547-550 (2004).
38. Lim W. Using low molecular weight heparin in special patient populations. J. Thromb. Thrombolysis 29, 233-240 (2010).
39. Sanderink GJ, Le Liboux A, Jariwala N et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin. Pharmacol. Ther. 72, 308-318 (2002).
40. Wilson SJ, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 31, 42-48 (2001).
41. Al-Yaseen E, Wells PS, Anderson J, Martin J, Kovacs MJ. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J. Thromb. Haemost. 3, 100-102 (2005).
42. Bazinet A, Almanric K, Brunet C et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb. Res. 116, 41-50 (2005).
43. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br. J. Surg. 90, 547-548 (2003).
44. Mayr AJ, Dunser M, Jochberger S et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb. Res. 105, 201-204 (2002).
45. Jimenez D, Diaz G, Iglesias A et al Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass. Arch. Bronconeumol. 44, 660-663 (2008).
46. Hainer J W, Barrett JS, Assaid CA et al Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study Thromb. Haemost. 87, 817-823 (2002).
47. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb. Res. 125, 220-223 (2010).
48. Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes. Surg. 18, 162-166 (2008).
49. Simone EP, Madan AK, Tichansky DS, Kuhl DA, Lee MD. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg. Endosc. 22, 2392-2395 (2008).
50. Kucher N, Leizorovicz A, Vaitkus PT et al Effcacy and safety of fxed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch. Intern. Med. 165, 341-345 (2005).
51. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes. Surg 12, 19-24 (2002).
52. Borkgren-Okonek MJ, Hart RW, Pantano JE et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratifcation, and antifactor Xa activity Surg Obes. Relat. Dis. 4, 625-631 (2008).
53. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med. 162, 1833-1840 (2002).
54. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br. J. Surg. 92, 1212-1220 (2005).
55. Raftopoulos I, Cortese-Hassett A, Gourash W et al. Pharmacokinetic properties of fondaparinux sodium in morbidly obese volunteers indicate that a single, weight-independent daily dose for thromboprophylaxis is feasible. Presented at: Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Philadelphia, PA, USA, 8-12 April 2008.
56. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: fndings of the Prophylaxis Against VTE Outcomes in Bariatric Surgery Patients Receiving Enoxaparin (PROBE) study. Obes. Surg 15, 1368-1374 (2005).
57. Turpie AG, Bauer KA, Caprini JA, Comp PC, Gent M, Muntz JE. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J. Thromb. Haemost. 9, 1854-1861 (2007).
58. Sapala JA, Wood MH, Schuhknecht MP, Sapala MA. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. Obes. Surg 13, 819-825 (2003).
59. Wu EC, Barba CA. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. Obes. Surg 10, 7-13 (2000).
60. Barba CA, Harrington C, Loewen M. Status of venous thromboembolism prophylaxis among bariatric surgeons: have we changed our practice during the past decade? Surg Obes. Relat. Dis. 5, 352-356 (2009).
61. Rajasekhar A, Crowther M. Inferior vena caval flter insertion prior to bariatric surgery: a systematic review of the literature. J. Thromb. Haemost. 8, 1266-1270 (2010).
62. Guyatt GH, Cook DJ, Jaeschke R, Pauker SG, Schunemann HJ. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 123S-131S (2008).
63. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 141S-159S (2008). (Pubitemid 351892966)
64. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann. Pharmacother. 43, 1064-1083 (2009).
65. Escalante-Tattersfeld T, Tucker O, Fajnwaks P et al. Incidence of deep vein thrombosis in morbidly obese patients undergoing laproscopic Roux-en-Y gastric bypass. Surg Obes. Relat. Dis. 4, 126-130 (2008).
66. Magee CJ, Barry J, Javed S, Macadam R, Kerrigan D. Extended thromboprophylaxis reduces incidence of postoperative venous thromboembolism in laparoscopic bariatric surgery. Surg. Obes. Relat. Dis. 6, 322-325 (2010).